Tae-Min Kim

65PUBLICATIONS
368CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (65)

|Oct 05, 2026
Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients.

|Sep 17, 2026
Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study.

|Aug 31, 2026
Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01.

|Jun 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

|Jun 01, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

|Apr 24, 2026
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.

Pageof 11

Frequent Collaborators

10 joint publications

Chul-Kee Park

7 joint publications

Dong-Wan Kim

7 joint publications

Sung-Hye Park

6 joint publications

Byoung Chul Cho